Table 1 Specific adverse events reported by participants who received a full course (28 days) or a short course (5 days) of the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate, one pill, once a day, as post-exposure prophylaxis (PEP) for sexual exposure to HIV infection

Total

218 (100.0)^a

50 (100.0)

At least one adverse event

132 (60.6 [54.0–67.1])

15 (30.0 [16.8–43.1])

Fatigue

57 (26.1 [20.3–32.0])

5 (10.0 [1.4–18.6])

Abdominal disorders

 - Nausea

55 (25.2 [19.4–31.0])

6 (12.0 [2.7–21.3])

 - Vomiting

5 (2.3 [0.3–4.3])

4 (8.0 [0.2–15.8])

 - Diarrhea

37 (17.0 [11.9–22.0])

1 (2.0 [0–6.0])

 - Abdominal pain

18 (8.3 [4.6–11.9])

0

 - Dysphagia

1 (0.5 [0–1.4])

0

 - Dysgueusia

1 (0.5 [0–1.4])

0

Headache

17 (7.8 [4.2–11.4])

3 (6.0 [0–12.8])

Vertigo

5 (2.3 [0.3–4.3])

0

Insomnia

3 (1.4 [0–2.9])

0

Visual trouble

1 (0.5 [0–1.4])

0

Arthralgia or myalgia

2 (0.9 [0–2.2])

0

Fever sensation

3 (1.4 [0–2.9])

0

Rash

2 (0.9 [0–2.2])

0

Cytolysis

3 (1.4 [0–2.9])

0